Allopurinol

Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect[1][2][3][4][5].

Product Specifications

CAS Number

[315-30-0]

UNSPSC

12352005

Hazard Statement

H301, H317

Target

Xanthine Oxidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Allopurinol.html

Purity

99.97

Solubility

DMSO : 14 mg/mL (ultrasonic; warming) |H2O : 1 mg/mL (ultrasonic; adjust pH to 11 with NaOH)

Smiles

O=C1C2=C(NN=C2)N=CN1

Molecular Formula

C5H4N4O

Molecular Weight

136.11

Precautions

H301, H317

References & Citations

[1]Pacher P, et al. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58 (1) :87-114.|[2]Pfaller MA, et al. Antileishmanial effect of allopurinol. Antimicrob Agents Chemother. 1974;5 (5) :469-472. |[3]Karve AV, et al. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J Pharmacol. 2013 May-Jun;45 (3) :244-7.|[4]Schmidt AP, et al. Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br J Pharmacol. 2009 Jan;156 (1) :163-72.|[5]Sun Y, et al. Dose-dependent effects of allopurinol on human foreskin fibroblast cells and human umbilical vein endothelial cells under hypoxia. PLoS One. 2015 Apr 1;10 (4) :e0123649.